Jan 3rd, 2025
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China’s National Medical Products Administration
MoreInnovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China’s National Medical Products Administration
MoreInnovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
MoreInnovent Receives Approval of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China’s National Medical Products Administration
More